Trends in the outpatient medication management of lupus erythematosus in the United States

Journal of Drugs in Dermatology

Volumn 13, Issue 5, 2014, Pages 545-552

  Sugai, Daniel Y ^a   Gustafson, Cheryl J ^a   De Luca, Jacqueline F ^a   Davis, Scott A ^a   Jorizzo, Joseph L ^a   O'Rourke, Kenneth S ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCLOMETASONE; ALPRAZOLAM; AMLODIPINE; ATENOLOL; AZATHIOPRINE; CALCIUM; CITALOPRAM; CLOBETASOL; DEXTROPROPOXYPHENE; ESOMEPRAZOLE; FLUOCINONIDE; FUROSEMIDE; HYDROXYCHLOROQUINE; LEVOTHYROXINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PAROXETINE; PREDNISONE; RANITIDINE; RECOMBINANT ERYTHROPOIETIN; ROFECOXIB; SERTRALINE; STEROID; SUCRALFATE; TRAMADOL; TRIAMCINOLONE; UNINDEXED DRUG; VITAMIN D; ZOLPIDEM;

ACNE; ALLERGIC RHINITIS; ANEMIA; ANXIETY; ARTHRITIS; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTACT DERMATITIS; DEPRESSION; DERMATOLOGIST; DIABETES MELLITUS; ESSENTIAL HYPERTENSION; FEMALE; HEALTH SURVEY; HUMAN; HYPOTHYROIDISM; KIDNEY DISEASE; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MYALGIA; MYOSITIS; OSTEOARTHRITIS; OUTPATIENT CARE; PHYSICIAN; POLYPHARMACY; PRESCRIPTION; RASH; REFLUX ESOPHAGITIS; RHEUMATOLOGY; ROSACEA; SJOEGREN SYNDROME; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES; ADOLESCENT; ADULT; AGED; AMBULATORY CARE; CHILD; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; HEALTH CARE SURVEY; LUPUS ERYTHEMATOSUS, DISCOID; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; OUTPATIENT; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH CARE SURVEYS; HUMANS; LUPUS ERYTHEMATOSUS, DISCOID; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OUTPATIENTS; PHYSICIAN'S PRACTICE PATTERNS; UNITED STATES; YOUNG ADULT;

EID: 84900546829     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev. 2004;3161:423-453.
2. Kuhn A. Ruland V, Bonsmann G. Cutaneous lupus erythematosus: Update of therapeutic options Part I. J Am Acad Dermatol. 2010.
3. Ippolito A, Petri M. An update on mortality in systemic lupus erythematosus. Clin Exp Rheumatol. 2008:26 (5 Suppl 51):S72-S79.
4. Bongu A. Chang E, Ramsey-Goldman R. Can morbidity and mortality of SLE be improved? Best Pract Res Clin Rheumatol. 2002;16(2):313-332.
5. Mok CC. Emerging drug therapies for systemic lupus erythematosus. Expert Opin Emerg Drugs. 2006:11(4):597-608.
6. Sanz I, Yasothan U. Kirkpatrick R Belimumab. Nat Rev Drug Discov. 2011;10(5):335-336.
7. Centers for Disease Control and Prevention. Ambulatory Health Care Data: National Ambulatory Medical Care Survey, http://www.cdc.gov/nchs/ahcdhtm. 2011. Accessed July 31, 2011.
8. US Census Bureau. US Census 2000 Demographic profiles. http://censtats census.gov/data/US/01000.pdf. 2011. Accessed August 3. 2011.
9. PaskoX Smart DR. Physician characteristics and distribution in the US. Chicago: AMA Press; 2004.
10. Association of American Medical Colleges. 2008 Physician Specialty Data. https://members.aamc.org/eweb/upload/2012%20Physician%20Specialty%20Data%208ook. pdf. 2008 November. Accessed June 19. 2013.
11. Lupus Foundation of America I. Lupus Foundation of America, Inc. http://www.lupus.org/education/stats.html. 2011. AccessedJuly31, 2011.
12. Petri M, Perez-Gutthann S, Longenecker JC, Hochberg M. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med. 1991:91(4):345-353.
13. Alarcon GS, Roseman J, Bartolucci AA et al. Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum. 1998;41(7):1173-1180.
14. Korbet SM, Schwartz MM, Evans J. Lewis EJ. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol. 2007;18(1):244-254.
15. Bernatsky S, Boivin JF, Joseph L et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550-2557.
16. Molokhia M, McKeigue P. Systemic lupus erythematosus: genes versus environment in high risk populations. Lupus. 2006;15(11):827-832.
17. Wahie S, Daly AK, Cordell HJ et al. Clinical and Pharmacogenetic Influences on Response to Hydroxychloroquine in Discoid Lupus Erythematosus: A Retrospective Cohort Study. J Invest Dermatol. 2011;10.
18. Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2009;(4): CD002954.
19. Roenigk HH, Jr., Martin JS, Eichorn P, Gilliam JN. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis. 1980:25(3):281-285.
20. Michalski JP, Kodner C. Systemic lupus erythematosus: safe and effective management in primary care. Prim Care. 2010;37(4):767-78, vii.
21. Centers for Disease Control and Prevention. Deaths: Preliminary Data for 2009. http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59-04.pdf. 2011. Accessed August 10, 2011.
22. Tan EM. Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982:25(11):1271-1277.
23. Petri M, Orbai AM, Alarcon GS et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686.
24. Hijmans W, Doniach D, Roitt IM, Holborow EJ. Serological overlap between lupus erythematosus, rheumatoid arthritis, and thyroid auto-immune disease. Br Med J. 1961;2(5257):909-914.
25. White RG, Bass BH, Williams E. Lymphadenoid goitre and the syndrome of systemic lupus erythematosus. Lancet. 1961;1(7173):368-373.
26. Kumar K, Kole AK, Karmakar PS, Ghosh A. The spectrum of thyroid disorders in systemic lupus erythematosus. Rheumatol Int. 2012;32(1):73-78.
27. Lazarus MN, Isenberg DA. Development of additional autoimmune diseases in a population of patients with primary Sjogren's syndrome. Ann Rheum Dis. 2005;64(7):1062-1064.